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I

atrogenic hypoglycemia is the limiting factor in the glycemic
management of diabetes.1 It causes recurrent illness in most people with type 1
diabetes mellitus and in many with advanced type 2 diabetes mellitus and is
sometimes fatal. It generally precludes maintenance of euglycemia over a lifetime of
diabetes and thus full realization of the benefits of glycemic control. Various mechanisms, discussed in this review, cause a vicious cycle of recurrent hypoglycemia.
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As plasma glucose levels fall, the physiologic defenses against hypoglycemia1,2 are
a decrease in the secretion of the glucose-lowering pancreatic beta-cell hormone
insulin, an increase in the secretion of the glucose-raising pancreatic alpha-cell
hormone glucagon, and in the absence of an increase in glucagon, an increase in
the secretion of the glucose-raising adrenomedullary hormone epinephrine. The
normal behavioral defense is carbohydrate ingestion, prompted by neurogenic
(autonomic) symptoms that largely originate from a sympathetic neural response.1
These defenses are illustrated in Figure 1. Their effectiveness ensures a continuous
supply of glucose to the brain.1
In people with diabetes, therapeutic insulin excess caused by treatment with
insulin, sulfonylureas, or glinides can initiate a hypoglycemic episode. Marked
absolute therapeutic insulin excess can occasionally cause hypoglycemia in patients with intact defenses against hypoglycemia1 (Fig. 2). Typically, however,
hypoglycemia occurs during less marked or even relative therapeutic insulin excess (insulin levels insufficient to cause hypoglycemia under most conditions but
high enough to cause it in the context of decreased exogenous glucose delivery
or endogenous glucose production, increased glucose use, or increased sensitivity to insulin1) in patients with compromised defenses against hypoglycemia.
Such patients — those with established type 1 diabetes or advanced type 2 diabetes1 — have beta-cell failure or absolute endogenous insulin deficiency (Fig. 2).
As plasma glucose levels fall, the compromised physiologic defenses include failure of insulin levels to diminish (in the absence of endogenous insulin secretion,
circulating insulin levels are a function of the absorption and clearance of injected insulin, not insulin secretion), failure of glucagon secretion to increase,1,5,6
and attenuated epinephrine secretion1,7-9 (Fig. 2). This combination of compromised physiologic defenses causes the clinical syndrome of defective glucose
counterregulation, which increases the risk of recurrent severe hypoglycemia by
a factor of 25 or more.1
The compromised behavioral defense, as plasma glucose levels fall, is the failure to ingest carbohydrates because of the absence of symptoms of hypoglycemia;
n engl j med 369;4
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Figure 1. Physiologic and Behavioral Defenses against Hypoglycemia in Humans.
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their absence reflects the attenuation of the sympathoadrenal response (largely the sympathetic
neural response)1 (Fig. 2). That attenuation causes
the clinical syndrome of hypoglycemia unawareness (or impaired awareness of hypoglycemia),
which increases the risk of recurrent severe hypoglycemia by a factor of 6 or more.1
A pivotal finding is that hypoglycemia attenuates defenses (including increased epinephrine
secretion and symptomatic defenses) against
subsequent hypoglycemia in nondiabetic persons10 and patients with type 1 diabetes.7 That
led to the concept of hypoglycemia-associated
autonomic failure (HAAF) in diabetes (Fig. 2).
According to this concept, recent hypoglycemia
n engl j med 369;4
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adrenomedullary epinephrine response, in
context of an insulin concentration that is not
reduced and glucagon secretion that is not increased) and hypoglycemia unawareness (largely
by attenuating the sympathetic neural response)
and thus a vicious cycle of recurrent hypoglycemia.1,7,8 With regard to the pathophysiological
mechanisms of HAAF, one needs to explain not
only the lack of a decrease in insulin and of an
increase in glucagon but also the attenuated
sympathoadrenal — adrenomedullary and sympathetic neural — responses to declining glucose concentrations.
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Loss of Insulin and Glucagon Responses

The mechanism underlying the failure of circulating insulin levels to fall as glucose levels fall in
patients with type 1 diabetes or advanced type 2
diabetes is straightforward. In the absence of endogenous insulin secretion (beta-cell failure), circulating insulin levels are simply a function of
the absorption and clearance of injected insulin.1
The mechanism of the lack of an increase in
glucagon is different from that of the attenuation of the sympathoadrenal responses.1 Loss of
the glucagon response precedes attenuation of
the epinephrine response,1,6,11 is independent of
diabetic autonomic neuropathy,1,7 and is not corrected by scrupulous avoidance of hypoglycemia.1,12
The lack of an increase in alpha-cell glucagon
secretion is also best attributed to beta-cell failure — specifically, the lack of a decrease in the
364
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rized here. First, loss of the insulin response and
loss of the glucagon response are correlated,6,11,14,15 and they develop early in the course
of type 1 diabetes6,11 but late in the course of
type 2 diabetes.8 Second, the glucagon response
to hypoglycemia is not critically dependent on
innervation. Normal glucagon secretion in response to hypoglycemia occurs in humans with
a transplanted (denervated) pancreas,16 as well
as in humans with spinal cord transections17
(and, thus, no sympathoadrenal outflow from
the brain to the islets) and dogs with a denervated pancreas18; glucagon secretion is also
normal in the perfused rodent pancreas and
perfused rodent and human islets. Thus, loss of
the glucagon response cannot be attributed to
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in type 1 diabetes and advanced type 2 diabetes
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Third, because there is a glucagon response
to administered amino acids in patients with
type 1 diabetes,5,19,20 loss of the glucagon response to hypoglycemia must be the result of
reduced signaling of functional alpha cells to
secrete glucagon during hypoglycemia. Fourth,
because insulin normally regulates glucagon
secretion in a reciprocal fashion in humans20-25
and laboratory animals, it follows that loss of
beta-cell insulin secretion would result in loss of
the signal of a decrease in insulin to increase
alpha-cell glucagon secretion, despite a low glucose level in the alpha cells (Fig. 3). This mechanism for loss of the glucagon response to hypoglycemia does not exclude the possibility of
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These data support the conclusion that in
diabetes characterized by an absolute deficiency
of endogenous insulin secretion — type 1 diabetes and advanced type 2 diabetes — the lack of
a decrease in beta-cell insulin secretion causes
the loss of an increase in alpha-cell glucagon
secretion as glucose concentrations fall in response to therapeutic hyperinsulinemia.1 The
lack of a decrease in insulin and the lack of an
increase in glucagon are prerequisites for defective glucose counterregulation but do not cause
defective glucose counterregulation or hypoglycemia unawareness. Those two components of
HAAF in diabetes develop only when the sympathoadrenal and symptomatic responses to hypoglycemia become attenuated1 (Fig. 2).
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Attenuation of Sympathoadrenal Responses

Attenuated sympathoadrenal responses to hypoglycemia are commonly caused by recent hypoglycemia1,7,8,10 but can also be caused by sleep27,28
or prior exercise.29 Unlike the loss of the insulin
and glucagon responses at the islet level, the alteration resulting in attenuated sympathoadrenal responses must reside within the central
nervous system (CNS) or its afferent or efferent
connections.
One limitation of research on the mechanism
underlying attenuated sympathoadrenal responses in humans has been the need for noninvasive
methods of measuring human brain function.
As discussed below, new techniques of positronemission tomography (PET), magnetic resonance
imaging, and magnetic resonance spectroscopy
are now addressing that need. Other limitations
are the failure of many studies to document
which patients with diabetes have HAAF (i.e.,
documented attenuation of the plasma epinephrine and neurogenic symptom responses to
controlled hypoglycemia) and which patients do
not and the failure to study the putative mechanisms of HAAF in both patient groups and nondiabetic controls. A more efficient approach is to
study a putative mechanism of HAAF in nondiabetic persons both before a period of hypoglycemia, when normal plasma epinephrine and
neurogenic symptom responses to controlled
hypoglycemia can be documented, and after a
period of hypoglycemia, when attenuated responses can be documented.10,30,31 Incidentally,
the findings that attenuated sympathoadrenal
and symptomatic responses to hypoglycemia can
be induced by recent hypoglycemia in nondiabetic persons10,30,31 and can be reversed by scrupulous avoidance of hypoglycemia in patients
with diabetes1,12 underscore the fact that these
key features of HAAF are functional rather than
structural (i.e., neuropathic) in origin.1
Hypotheses regarding CNS-mediated mechanisms of the attenuated sympathoadrenal responses to hypoglycemia that cause HAAF include the systemic-mediator hypothesis, the brain
fuel–transport hypothesis, the brain-metabolism hypothesis, and the cerebral-network hypothesis.1,32,33
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tenuate the sympathoadrenal and symptomatic
responses to subsequent hypoglycemia.34,35 However, neither prior cortisol elevations similar to
those that occur during hypoglycemia36,37 nor
inhibition of the cortisol response to prior hypoglycemia with metyrapone37 prevents the attenuated epinephrine and symptomatic responses to
subsequent hypoglycemia in humans.
Brain Fuel–Transport Hypothesis

According to this hypothesis, recent hypoglycemia causes increased blood-to-brain transport of
glucose (or of an alternative metabolic fuel) and
thus attenuates sympathoadrenal and symptomatic responses to subsequent hypoglycemia.1
This hypothesis was initially based on the finding that hypoglycemia persisting for 3 days38 or
longer39 results in increased expression of glucose transporter 1 (GLUT-1) in the cerebral vasculature and in increased brain glucose uptake in
rats. However, hypoglycemia for just 2 hours results in attenuated sympathoadrenal and symptomatic responses to subsequent hypoglycemia
in humans.10 In addition, brain glucose uptake
(calculated from arteriovenous glucose differences across the brain and estimates of cerebral
blood flow [the Kety–Schmidt technique]) was
reported to be maintained during a subsequent
episode of hypoglycemia in nondiabetic persons
with a prior episode40 and in patients with type 1
diabetes who had relatively low glycated hemoglobin levels and thus probably more recent hypoglycemia.41 In both instances, however, the
difference in calculated brain glucose uptake was
due to greater estimated cerebral blood flow
rather than increased arteriovenous glucose differences across the brain.
The glucose-transport hypothesis was not supported by PET measurements. Global blood-tobrain glucose transport, measured with [1-11C]
glucose PET, was not reduced in patients with
poorly controlled type 1 diabetes42 and was not
increased after nearly 24 hours of interprandial
hypoglycemia,30 which produces a model of
HAAF (including attenuated epinephrine and
neurogenic symptom responses to hypoglycemia) in nondiabetic persons.30,31 Furthermore,
global blood-to-brain [11C]3-O-methylglucose
transport43 and [18F]deoxyglucose transport,44
Systemic-Mediator Hypothesis
both measured with PET, were not increased in
This hypothesis holds that increased circulating patients with type 1 diabetes who were thought
cortisol levels or perhaps some other factor dur- to have hypoglycemia unawareness.
ing recent hypoglycemia acts on the brain to atThe brain fuel–transport hypothesis may be
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flawed. The premise is that hypoglycemia causes
a decrease in the rate of cerebral glucose metabolism, which in turn causes an increase in sympathoadrenal activity, and that prior hypoglycemia may somehow increase the cerebral transport
of glucose to the brain, minimizing the decrease
in the rate of cerebral glucose metabolism and
thus attenuating the increase in sympathoadrenal activity. However, there is no evidence that a
decrease in the rate of cerebral glucose metabolism causes an increase in sympathoadrenal activity (that response could be a signaling event),
and it is unclear how low the plasma glucose
concentration has to be to limit oxidative brain
metabolism, but it may be quite low. The rate of
blood-to-brain glucose transport exceeds the rate
of cerebral glucose metabolism even at plasma
glucose concentrations of 65 mg per deciliter
(3.6 mmol per liter) in humans.30,42
Extrapolation of the linear relationship between plasma and brain glucose concentrations,
the latter measured with 13C magnetic resonance
spectroscopy, in nondiabetic persons and patients
with type 1 diabetes during euglycemia and hypoglycemia, as reported by van de Ven and colleagues,45 suggests that the plasma glucose
concentration at which the brain glucose concentration would become zero — at which point
brain glucose metabolism would have to decrease
— is less than 36 mg per deciliter (2.0 mmol per
liter). An increase in blood-to-brain glucose
transport would not increase brain glucose metabolism unless it shifted from below to above
that unknown, but seemingly low, glycemic
threshold.
There was no significant difference in brain
glucose concentrations between the nondiabetic
persons and the patients with type 1 diabetes in
the study by van de Ven and colleagues,45 suggesting no difference in blood-to-brain glucose
transport. Assuming the patients with type 1
diabetes did not have HAAF (epinephrine responses in these patients were similar to those
in nondiabetic persons, and symptoms of hypoglycemia were not reported), commentators suggested that blood-to-brain glucose uptake might
have been increased in patients with HAAF, if
they had been included in the study.46 That inference was made on the basis of two observations: a 15% higher occipital–cortical brain
glucose concentration in patients with type 1
diabetes than in nondiabetic persons, as measured with 1H magnetic resonance spectroscopy
n engl j med 369;4

under nonphysiologic conditions (infusions of
somatostatin, insulin, and 50% glucose) with
hyperglycemia (approximately 300 mg per deciliter [16.7 mmol per liter]),47 and no significant
difference in cortical brain glucose metabolism,
as measured with 13C magnetic resonance spectroscopy under similar nonphysiologic conditions with hyperglycemia, between patients with
type 1 diabetes and nondiabetic persons.48 Although the patients with type 1 diabetes were
assumed to have HAAF, they were not shown to
have attenuated epinephrine and symptomatic
responses to hypoglycemia.
Notably, the same investigative group found
no effect of recurrent episodes of hypoglycemia,
which produced a model of HAAF (attenuated
epinephrine and neurogenic symptom responses
to hypoglycemia), on brain glucose concentrations measured with 1H magnetic resonance
spectroscopy under similar nonphysiologic conditions with hyperglycemia.49 Because the brain
glucose concentration is a direct function of the
plasma glucose concentration,45 the unaltered
brain glucose concentration does not support the
conclusion that increased blood-to-brain glucose
transport might be the mechanism of HAAF.46
If the normally small astrocytic brain glycogen pool1 increases substantially (reflecting glycogen supercompensation) after hypoglycemia,
that expanded source of glucose within the brain
could result in an attenuated sympathoadrenal
response during subsequent hypoglycemia.50
However, the evidence in rats that brain glycogen content increases substantially after hypoglycemia has not been confirmed,51 and the
glycogen-supercompensation hypothesis has not
been supported in humans.52 Brain glycogen
was not increased in patients with type 1 diabetes who were selected for hypoglycemia unawareness. Because brain glycogen synthesis is a
direct function of the plasma glucose concentration and blood-to-brain glucose transport, increased blood-to-brain glucose transport should
result in increased brain glycogen. That was not
the case in the patients selected for hypoglycemia unawareness.52
Neurons oxidize lactate,53 but that lactate is
largely derived from glucose within the brain.1
An increase in blood-to-brain lactate transport is
a plausible mechanism of HAAF, although, as discussed above regarding glucose, this idea assumes that a decrease in brain oxidative metabolism causes an increase in sympathoadrenal
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activity and, if so, lactate metabolism would
have to be sufficient to raise brain oxidative
metabolism. Lactate infusions resulting in increases in circulating lactate levels by a factor of
approximately 4 in nondiabetic persons54 and by
approximately 2 in nondiabetic persons and patients with type 1 diabetes55,56 reduced epinephrine responses to, and symptoms of, hypoglycemia in both the nondiabetic persons and the
patients with type 1 diabetes. Plasma lactate
concentrations roughly double during hyperinsulinemia.20 Arteriovenous measurements have
revealed lactate release from the brain in the
euglycemic state and either no lactate uptake57
or a small amount of lactate uptake, sufficient to
compensate for only about 25% of the calculated
brain glucose energy deficit58 during hyperinsulinemic hypoglycemia in humans.
Studies of systemic lactate infusions with 13C
magnetic resonance spectroscopic measurements
in nondiabetic persons have shown brain lactate
uptake when arterial lactate levels are increased
by a factor of 4 and increased lactate transport
to the brain when plasma lactate levels are increased by a factor of 2.59,60 Indeed, increased
brain lactate concentrations without increased
oxidation of lactate have been reported in patients with type 1 diabetes.61 Lactate infusions
that caused only a small increase in brain lactate
metabolism were found to result in maintenance
of brain glucose metabolism during subsequent
hypoglycemia in rats subjected to recurrent hypoglycemia.62
Brain-Metabolism Hypothesis

This hypothesis holds that recent hypoglycemia
alters CNS metabolic regulation, resulting in attenuated sympathoadrenal responses to declining
plasma glucose concentrations and thus HAAF.
Studies of the cellular and molecular biology and
pathophysiology of CNS control of glucose counterregulation in rodent models have focused
largely, but not exclusively, on the ventromedial
hypothalamus. Potential mechanisms32,33,63-65 include decreased glucose sensing by glucose-excited
or glucose-inhibited neurons in the hypothalamus, elsewhere in the brain, and in the periphery;
decreased activation of AMP kinase; increased
glucokinase activity; loss of a decrease in the
counterregulatory inhibitor γ-aminobutyric acid;
loss of an increase in the counterregulatory stimulator glutamine; increased urocortin release;
and reduced actions of insulin on the brain.
368
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One or more of these basic clues from a
v ariety of studies may ultimately lead to clinical
strategies that prevent hypoglycemia. Pending
that, there are clues from studies in humans that
may lead to strategies that lower the barrier of
hypoglycemia in diabetes66 (Fig. 4).
Several agents, such as glucagon, glucagonstimulating amino acids, β2-adrenergic agonists
(e.g. terbutaline), and adenosine antagonists (e.g.,
caffeine), are known to raise glucose concentrations. Their therapeutic potential is limited because their glucose-raising actions are not increased in response to falling glucose levels.66
Nonetheless, the judicious use of such agents
could prove beneficial if their efficacy and safety
were demonstrated in randomized clinical trials.
Five potential treatments for reversing glucose counterregulatory defects66 — selective
serotonin-reuptake inhibitors (SSRIs),67,68 adrenergic antagonists,69 an opiate-receptor antagonist,70,71 fructose,72 and a selective ATP-sensitive
potassium (KATP)–channel agonist73 — are of
particular interest. All enhance counterregulatory
responses to falling glucose concentrations.66
SSRIs increase the counterregulatory responses to hypoglycemia in humans67 and rats.68 A
randomized clinical trial of an SSRI for the prevention of iatrogenic hypoglycemia may be warranted. Combined α-adrenergic and β-adrenergic
blockade prevents the attenuation of sympathoadrenal responses the day after hypoglycemia in
humans.69 If that were shown to be predominantly an effect of β1-adrenergic blockade, a
trial of a β1-adrenergic antagonist for the prevention of hypoglycemia in patients with type 1
diabetes would be reasonable and might reduce
mortality.74 β1-adrenergic blockade would not
impair the β2-adrenergic actions of catecho
lamines, such as their glucose-raising and symptom-generating effects. Infusion of the opioidreceptor antagonist naloxone increases the plasma
epinephrine response to hypoglycemia and, when
administered during hypoglycemia, prevents attenuation of the plasma epinephrine response to
subsequent hypoglycemia in humans.70,71 Fructose
infusion amplifies epinephrine and glucagon
responses and increases glucose production during hypoglycemia in humans.72 Finally, administration of a selective Kir6.2/SUR-1 K ATP-channel
agonist increases the epinephrine response to
hypoglycemia in rats.73 However, systemic administration of the nonselective K ATP -channel
agonist diazoxide suppresses the glucagon re-

nejm.org

july 25, 2013

The New England Journal of Medicine
Downloaded from nejm.org at WASHINGTON UNIV SCH MED MEDICAL LIB on March 19, 2014. For personal use only. No other uses without permission.
Copyright © 2013 Massachusetts Medical Society. All rights reserved.

mechanisms of disease

Cure diabetes

Develop plasma glucose
regulation:
Insulin replacement
Insulin secretion

Prevent diabetes

Eliminate Hypoglycemia

Reverse compromised glucose
counterregulatory defenses

Glucagon
Amino acids
β2-adrenergic agonist

Adrenergic antagonist
Selective serotonin-reuptake
inhibitor
Opiate antagonist

Adenosine antagonist
GABA-release inhibitor
Fructose
KATP-channel agonist
Other

Figure 4. Elimination of Hypoglycemia from the Lives of People with Diabetes.
Prevention or cure of diabetes or provision of plasma-glucose–regulated insulin replacement or secretion would
eliminate hypoglycemia. In the meantime, available drugs might reduce the burden of iatrogenic hypoglycemia.
GABA denotes γ-aminobutyric acid, and K ATP ATP-sensitive potassium. Adapted from Cryer.66

sponse and has no effect on the epinephrine reRecent hypoglycemia attenuates sympathoadsponse to hypoglycemia in nondiabetic humans.22 renal responses to subsequent hypoglycemia in
nondiabetic persons10 and in patients with diaCerebral-Network Hypothesis
betes,7 an example of habituation of the sympaAccording to this hypothesis, recent hypoglyce- thoadrenal response to hypoglycemia in humans.
mia acts through a network of interconnected Hypoglycemia has been found to increase synapbrain regions to inhibit hypothalamic activation tic activity in the human dorsal midline thalaand thus attenuate the sympathoadrenal and mus, among other brain sites,31,75,76 and to insymptomatic responses to subsequent hypogly- crease synaptic activity to a greater extent after
cemia.1,31 The cerebral-network hypothesis is recent hypoglycemia only in the dorsal midline
largely based on findings from functional neuro- thalamus (Fig. 5),31 the site of the posterior
imaging in humans during hypoglycemia,43,44 paraventricular nucleus of the thalamus.78 Inparticularly [15O]water PET measurements of re- deed, slightly subphysiologic glucose concentragional cerebral blood flow as an index of region- tions (65 mg per deciliter) increase synaptic
al brain synaptic activity,31,75,76 and the psycho- activity in the dorsal midline thalamus prephysiological concept of habituation of the dominantly, perhaps selectively, in humans.80
response to a given stress and its proposed Thus, thalamic synaptic activation may be inmechanism.77 The posterior paraventricular nu- volved in the pathogenesis of the attenuated
cleus of the thalamus is a brain site at which sympathoadrenal and symptomatic responses to
previous stress, such as stress induced by re- hypoglycemia that are the key features of HAAF
straint, acts to attenuate responses to subsequent in diabetes.31,80
episodes of that stress in rats.78 Lesions in the
Inactivation of the medial prefrontal cortex
posterior paraventricular nucleus of the thalamus has also been reported to prevent habituation
block habituation of the hypothalamic–pituitary– to restraint-induced stress in rats.81 Increased
adrenocortical response to repeated restraint.78 synaptic activity in the medial prefrontal cortex
Habituation of the sympathoadrenal response to (anterior cingulate) occurs during hypoglycerepeated restraint-induced stress has also been mia in humans.31,75,76 Thus, the medial predocumented in rats.79
frontal cortex, among other regions, may be
n engl j med 369;4
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reported in patients with type 1 diabetes and
hypoglycemia unawareness, as compared with
those without hypoglycemia unawareness.44 Indeed, the array of differences in the patterns of
[18F]deoxyglucose uptake during hypoglycemia
between patients with hypoglycemia unawareness and those without it44 is consistent with the
participation of a widespread cerebral network
in the pathogenesis of HAAF in diabetes.

12

Day 1

Thalamus

of

0
12

Sum m a r y
Day 2

0

Figure 5. Increased Thalamic Response to Hypoglycemia in a Model of HAAF.
A model of HAAF in humans shows a greater increase in dorsal midline
thalamus activation, as measured with the use of [15O]water positron-emission
tomography, during hypoglycemia on day 2 than during hypoglycemia on
day 1, with interprandial hypoglycemia occurring between the measurements on day 1 and day 2. Areas with the greatest activity are yellow, and
those with the least activity are dark red. Adapted from Arbeláez et al.31

part of the cerebral network involved in the
attenuated sympathoadrenal and symptomatic
responses to hypoglycemia that characterize
HAAF in diabetes.
A greater decrease in [18F]deoxyglucose uptake, measured with the use of PET, in the subthalamic region of the brain, centered on the
hypothalamus, during hypoglycemia has been

The key feature of HAAF in diabetes is attenuated sympathoadrenal responses to hypoglycemia,
most often caused by recent hypoglycemia. In the
context of the lack of a decrease in insulin and of
an increase in glucagon — both plausibly attributed to beta-cell failure — attenuation of the epinephrine response causes defective glucose counterregulation. Attenuation of the sympathetic
neural response largely causes hypoglycemia unawareness. The precise mechanisms of the attenuated sympathoadrenal responses are not known,
but there are provocative clues, ranging from evidence that available drugs might lower the burden of iatrogenic hypoglycemia and that lactate
can affect brain metabolism to the notion of alterations in a cerebral network in the pathogenesis of HAAF.
Disclosure forms provided by the author are available with the
full text of this article at NEJM.org.
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